The effects of intravitreally injected dexamethasone implant and anti-VEGF on macular edema due to retinal vein occlusion

dc.authorid-en_US
dc.authorid-en_US
dc.authorscopusid57204620975en_US
dc.authorscopusid55752565900en_US
dc.authorwosid-en_US
dc.authorwosid-en_US
dc.contributor.authorYıldız, Aydın
dc.contributor.authorArıkan, Sedat
dc.date.accessioned2023-03-14T12:13:53Z
dc.date.available2023-03-14T12:13:53Z
dc.date.issued2021en_US
dc.departmentFakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü
dc.description.abstractAim: In this study, we aimed to investigate the efficacy of intravitreal treatment modalities for macular edema secondary to central retinal vein occlusion (CRVO) and branchial retinal vein occlusion (BRVO). Material and Methods: A total 58 patients with macular edema secondary to CRVO and BRVO were included in this retrospective study. The patients followed up between 2012 and 2018 were subjected to either intravitreal dexamethasone (DEX) implant injection (Group 1), or intravitreal anti-vascular endothelial growth factor (anti-VEGF) containing ranibizumab injection (Group 2). Additionally, the patients who received the combination of intravitreal DEX and anti-VEGF treatment (Group 3) were also assessed in this study. The degree of central macular thickness (CMT) using optical coherence tomography, and best -corrected visual acuity (BCVA) levels were evaluated in all groups before and after treatment. Results: CRVO and BRVO were present in 12 and 46 patients, respectively, and the mean follow- up time was 38 months. The mean CMT values measured in pretreatment vs. posttreatment period in Group 1, Group 2 and Group 3 were 448±41.3μm vs.217.7±15.9μm (p<0.05), 492±38.5μm vs.249.3±13.8μm (p<0.05), and 562.5±85.7μm vs.330.3±55.9μm (p<0.05), respectively. Regarding the comparison of BCVA levels measured in the pretreatment vs. postreatment period, there was a statistically significant increase in all groups as follows: 0.8±0.08 logMAR vs. 0.4±0.08 logMAR (p<0.05) in Group 1, 0.9±0.1 logMAR vs. 0.3±0.05 logMAR ( p<0.05) in Group 2, and 1.6±0.3 logMAR vs. 0.5±0.1 logMAR( p<0.05) in Group 3.Discussion: The intravitreal injection treatments with either dexamethasone implant or anti-VEGFs can have a potential effects on the resolution of macular edema secondary to BRVO. Moreover, their combination can be beneficial for the persistent macular edema arising from CRVO.en_US
dc.identifier.citationYıldız, A., Arıkan, S. (2021). The effects of intravitreally injected dexamethasone implant and anti-VEGF on macular edema due to retinal vein occlusion. Annals of Clinical and Analytical Medicine, 12(6), 663-666. doi:10.4328/ACAM.20378.en_US
dc.identifier.doi10.4328/ACAM.20378
dc.identifier.endpage666en_US
dc.identifier.issn2667-663X
dc.identifier.issue6en_US
dc.identifier.startpage663en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12428/3817
dc.identifier.volume12en_US
dc.identifier.wosWOS:000732052100015
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.institutionauthorYıldız, Aydın
dc.institutionauthorArıkan, Sedat
dc.language.isoen
dc.publisherBayrakol Medical Publishingen_US
dc.relation.ispartofAnnals of Clinical and Analytical Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/us/*
dc.subjectRetinal vein occlusionen_US
dc.subjectIntravitreal injectionsen_US
dc.subjectDexamethasone implanten_US
dc.subjectAflibercepten_US
dc.subjectRanibizumaben_US
dc.titleThe effects of intravitreally injected dexamethasone implant and anti-VEGF on macular edema due to retinal vein occlusion
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Aydin_Yildiz_Makale.pdf
Boyut:
136.38 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Araştırma Makalesi
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: